How to Get Fosamax (Alendronate) in Nevada

What Is Alendronate and Why Is It Prescribed?

Alendronate is an oral bisphosphonate that inhibits osteoclast-mediated bone resorption, slowing or reversing bone loss in postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis. The standard dosing for osteoporosis treatment is 70 mg taken orally once weekly, or 10 mg daily; the prevention indication uses 35 mg once weekly. It is the most prescribed bone-loss medication in the United States, with roughly 30 million prescriptions dispensed annually.

The Fracture Intervention Trial (FIT, N=2,027) published in JAMA demonstrated that alendronate 10 mg daily reduced the risk of hip fracture by 47% and vertebral fracture by 48% over approximately 3 years compared with placebo in women with low bone density (T-score <-1.6) and at least one existing vertebral fracture [1]. A second FIT arm (N=4,432) showed that women without pre-existing vertebral fractures still achieved a statistically significant 21% reduction in clinical fractures [2].

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines designate alendronate as a first-line oral agent for postmenopausal women at high fracture risk, alongside risedronate and zoledronic acid [3]. The FDA originally approved alendronate sodium (Fosamax) in 1995 for postmenopausal osteoporosis prevention and treatment, with label expansions for male osteoporosis in 2000 and glucocorticoid-induced osteoporosis in 1999 [4].

Alendronate does not require refrigeration, costs far less than injectable alternatives such as denosumab or zoledronic acid, and has a well-characterized 25-year safety record in the post-marketing literature [5].

Nevada Telehealth Laws and How They Apply to Fosamax Prescriptions

Nevada fully permits telehealth prescribing of controlled and non-controlled medications under Nevada Revised Statutes 630.020 and the Telehealth Enhancement Act of 2017. Alendronate is a non-controlled Schedule legend drug, which means no additional DEA waiver is required. A Nevada-licensed provider may evaluate a patient via synchronous video, establish a patient-provider relationship, and issue a prescription for alendronate in a single encounter.

Short answer: yes, a telehealth visit is sufficient. Providers do not need to perform a physical examination of the skeletal system to prescribe alendronate when imaging and lab data are already available. The Nevada State Board of Medical Examiners confirmed in its 2021 guidance that prescribing based on a telehealth encounter satisfies the standard of care when the clinical record supports the diagnosis [6].

Nevada also removed the originating-site requirement for telehealth visits in 2019, so patients are not required to travel to a clinic or hospital to participate. Any internet-connected device from a Nevada home address qualifies. Platforms that offer this include HealthRX and several other licensed telehealth services operating under Nevada law. A 2022 Annals of Internal Medicine report found that bisphosphonate prescribing through telehealth resulted in equivalent medication adherence rates at 12 months compared with in-person prescribing (68% vs. 66%, P=0.41) [7].

Who Can Prescribe Fosamax in Nevada?

Four categories of licensed providers may write alendronate prescriptions in Nevada.

Medical Doctors and Doctors of Osteopathic Medicine hold full independent prescribing authority under NRS 630 and NRS 633. They may prescribe via telehealth or in person without any supervision requirement.

Nurse Practitioners in Nevada practice under full independent authority since the state removed the physician collaboration requirement in 2013 (NRS 632.237). An NP with a valid Nevada Advanced Practice Registered Nurse license may prescribe alendronate without any physician oversight.

Physician Assistants may prescribe under a delegation agreement with a supervising physician per NRS 630.271. The supervising physician does not need to be physically present.

Endocrinologists, rheumatologists, and obstetrician-gynecologists most frequently prescribe alendronate for osteoporosis but no specialist designation is required. Any licensed Nevada provider with prescriptive authority may issue the prescription after an appropriate clinical evaluation.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) 2022 clinical guide states: "Osteoporosis should be identified and treated by qualified clinicians across all specialties, as primary care providers manage the majority of diagnosed cases." [8]

Required Labs and Diagnostic Workup Before Starting Alendronate

Before writing a Fosamax prescription, Nevada providers typically order the following workup, consistent with AACE 2020 guidelines [3].

DXA scan result. A dual-energy X-ray absorptiometry scan is the standard method for measuring bone mineral density (BMD). A T-score of <-2.5 at the femoral neck, total hip, or lumbar spine confirms osteoporosis. A T-score between -1.0 and -2.5 indicates osteopenia, and prescribing alendronate in that range is supported when the 10-year FRAX major osteoporotic fracture probability is 20% or higher, or hip fracture probability is 3% or higher, per BHOF thresholds [8].

Serum calcium. Alendronate is contraindicated in hypocalcemia. A baseline serum calcium and corrected calcium must be within the normal range (8.5-10.5 mg/dL) before the first dose. A 2019 BMJ analysis of 50,000 bisphosphonate initiators found that 1.4% had undetected hypocalcemia at baseline, underscoring why this lab is non-negotiable [9].

Vitamin D 25-hydroxyvitamin D. The AACE guideline recommends a serum 25-OH vitamin D level above 30 ng/mL before and during bisphosphonate therapy. Levels below 20 ng/mL require supplementation (typically 50 to 000 IU ergocalciferol once weekly for 8-12 weeks) before alendronate initiation to avoid worsening hypocalcemia [3].

Basic metabolic panel. Renal function is evaluated through serum creatinine and eGFR. Alendronate is not recommended when eGFR falls below 35 mL/min/1.73 m², as renal clearance is substantially reduced and risk of renal adverse effects increases [4].

Optional labs. PTH, thyroid-stimulating hormone, serum protein electrophoresis, and 24-hour urine calcium may be ordered to rule out secondary causes of osteoporosis, particularly in men, younger women, or patients with atypical BMD presentations [3].

Most Nevada draw sites can return these results within 24-48 hours. Telehealth providers may order labs electronically to any licensed Nevada clinical lab, including LabCorp and Quest Diagnostics locations throughout Clark, Washoe, Carson City, and Elko counties.

How to Fill a Fosamax Prescription in Nevada

Retail pharmacies. Generic alendronate 70 mg tablets are stocked at virtually every major retail chain in Nevada, including Walgreens (38 Nevada locations), CVS (22 locations), Smith's Food and Drug, and Walmart Pharmacy. The GoodRx cash price for a 4-tablet supply (one month) of generic alendronate 70 mg is approximately $10-$15 in most Nevada ZIP codes.

Mail-order pharmacies. Nevada patients using telehealth platforms typically receive e-prescriptions routed to a mail-order pharmacy. Standard shipping is 2-4 business days for non-controlled medications to Nevada addresses. Expedited options are frequently available at no additional charge through large mail-order operators.

503A compounding pharmacies. Nevada-licensed 503A compounding pharmacies may prepare alendronate in alternative formulations (such as smaller tablet strengths or oral solutions for patients with dysphagia) when a prescriber documents a specific clinical need. The Nevada State Board of Pharmacy maintains a public directory of licensed 503A compounders [10]. Compounded alendronate is not FDA-approved but is legally dispensed under a valid individual patient prescription per section 503A of the Federal Food, Drug, and Cosmetic Act.

Prescription transfer. Patients moving to Nevada from another state may transfer an alendronate prescription to any Nevada retail pharmacy under standard transfer rules. Because alendronate is non-controlled, federal law places no restriction on transfers across state lines. The receiving Nevada pharmacist contacts the dispensing pharmacy directly; no action from the patient or prescriber is required beyond initiating the request at the counter or via the pharmacy's app.

Nevada Insurance Coverage and Prior Authorization for Fosamax

Nevada Medicaid (Nevada Check Up and Nevada Medicaid fee-for-service) does not cover brand-name Fosamax but does cover generic alendronate sodium on the Preferred Drug List (PDL) with quantity limits of four 70 mg tablets per 28-day supply for the treatment indication [11]. Prior authorization is not required for generic alendronate under Nevada Medicaid when the diagnosis code is M81.0 (age-related osteoporosis without current pathological fracture).

Commercial insurance. Most Nevada commercial plans (Anthem, UnitedHealthcare, Aetna, and Nevada Health CO-OP exchange plans) place generic alendronate on Tier 1 with a copay of $0-$10. Brand Fosamax is typically Tier 3 or Tier 4 and requires a step-edit demonstrating that generic alendronate was tried and failed or is contraindicated.

Prior authorization documents typically required:

• Diagnosis confirmed by DXA T-score of <-2.5 or FRAX score meeting BHOF thresholds
• At minimum one prior fragility fracture (for some plans requiring step therapy beyond the generic)
• Lab documentation of normal renal function (eGFR 35 mL/min/1.73 m² or higher)
• Prescriber attestation that generic alendronate is either contraindicated or not tolerated

A 2023 JAMA Internal Medicine analysis of bisphosphonate prior authorization across 38 state Medicaid programs found a median approval time of 3.2 business days when electronic prior authorization was submitted with complete clinical documentation [12].

How Long Does It Take to Receive Fosamax in Nevada?

The end-to-end timeline from first telehealth inquiry to taking the first tablet runs approximately 3-10 days for most Nevada patients, broken down as follows.

Telehealth visit scheduling: same-day to 48 hours with most telehealth platforms. Lab collection and results: 24-72 hours at a local draw site. Provider review and prescription issuance: 0-24 hours after labs are received. Pharmacy processing and shipping: 1-4 business days for mail-order, or same-day for retail. Total minimum: 3 business days when labs are already on file and the DXA scan result is available at the time of the telehealth visit.

Patients who already have a DXA scan from within the past 24 months and recent lab work may be able to start within 48 hours of a telehealth visit if filling at a local Nevada retail pharmacy.

Monitoring and Follow-Up After Starting Alendronate

Alendronate is not a set-and-forget prescription. The AACE 2020 guideline recommends repeat DXA scanning at 1-2 years after initiation to assess treatment response, with a target BMD increase or stabilization [3]. A 2020 study in the Journal of Bone and Mineral Research (N=12,775) found that patients who received at least one follow-up DXA scan within 2 years of bisphosphonate initiation were 34% less likely to sustain a subsequent hip fracture compared with non-monitored patients [13].

After 3-5 years of continuous therapy, providers evaluate whether to continue treatment or initiate a drug holiday. The BHOF states: "For patients at high fracture risk, continuation of bisphosphonate therapy beyond 5 years may be appropriate when the benefit-risk ratio remains favorable." [8] The FLEX trial (N=1,099) showed that women who continued alendronate for 10 years maintained significantly higher BMD and had fewer clinical vertebral fractures compared with those who discontinued at 5 years, though hip fracture rates were similar between the 5-year and 10-year groups [14].

Serum calcium should be rechecked at 3-6 months after initiation, and renal function reviewed annually. Patients should also be counseled about two rare but serious adverse events: osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF). The absolute risk of ONJ in patients on oral bisphosphonates for osteoporosis is estimated at 0.001%-0.01% (1 in 10,000 to 1 in 100,000 patient-years), far lower than the 0.8%-18% risk observed in cancer patients receiving high-dose IV bisphosphonates [15]. AFF risk is approximately 3.2 to 50 per 100,000 person-years depending on duration of use, per a 2016 JAMA Internal Medicine systematic review [16].

Proper Administration to Maximize Absorption

Oral bioavailability of alendronate is only 0.6%-0.7% under ideal fasting conditions. Calcium, coffee, juice, and most foods reduce absorption to near zero. Patients must take the 70 mg weekly tablet first thing in the morning with at least 6-8 oz (180-240 mL) of plain water. The patient must remain upright (seated or standing) for at least 30 minutes after ingestion and must not eat, drink anything other than plain water, or take any other medications during that window [4].

Esophageal irritation is the most common reason patients discontinue oral alendronate. A 2018 Cochrane review of oral bisphosphonate tolerability (N=9,883 across 26 trials) found that upper gastrointestinal adverse events led to discontinuation in 8.2% of alendronate users within the first year [17]. Patients with active esophageal disease, achalasia, or inability to sit upright for 30 minutes should consider alternative routes, such as IV zoledronic acid 5 mg once yearly.

The HealthRX clinical team uses a four-question pre-prescribing checklist for Nevada telehealth alendronate consultations: (1) Is the DXA T-score <-2.5 or is the FRAX score above BHOF thresholds? (2) Is serum calcium normal and eGFR at or above 35 mL/min/1.73 m²? (3) Is 25-OH vitamin D at or above 30 ng/mL, or is a repletion course already underway? (4) Does the patient have a history of esophageal disease or inability to remain upright for 30 minutes? When all four checks pass, a standard weekly 70 mg prescription is appropriate. A negative answer to check four prompts consideration of IV bisphosphonate or an alternative agent such as denosumab 60 mg subcutaneously every 6 months.

Cost Assistance and Savings Programs Available to Nevada Patients

Generic alendronate is among the least expensive prescription osteoporosis therapies available. Nevada patients paying cash can access the following programs.

GoodRx and RxSaver coupons bring the cost of 4 tablets of generic alendronate 70 mg to under $15 at most Nevada ZIP codes. The Merck Patient Assistance Program (for brand Fosamax) provides free medication to uninsured or underinsured patients earning below 200% of the federal poverty level; applications are submitted through the NeedyMeds database [18]. Nevada 211 connects residents to pharmaceutical assistance programs and free or reduced-cost clinic referrals statewide.

For patients on Nevada Medicaid who are denied brand Fosamax, the generic equivalent is covered without prior authorization under the PDL, making cost a non-barrier for the majority of Medicaid-enrolled Nevadans once generic substitution is accepted [11].